Advanced search
Publication Cover
Artificial Cells, Nanomedicine, and Biotechnology
An International Journal
Volume 44, 2016 - Issue 1
Submit an article Journal homepage
14,911
Views
192
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

Nanostructured lipid carriers and their current application in targeted drug delivery

Piyush JaiswalUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India
,
Bina GidwaniUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India
&
Amber VyasUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, IndiaCorrespondence[email protected]
Pages 27-40 | Received 05 Jan 2014, Accepted 26 Mar 2014, Published online: 09 May 2014

Figures & data

Figure 1. Important aspects of nanocarriers.
Figure 1. Important aspects of nanocarriers.
Figure 2. Colloidal nano delivery systems, modified after (Muller et al. 2009).
Figure 2. Colloidal nano delivery systems, modified after (Muller et al. 2009).

Table I. Types of NLCs (CitationWestesen et al. 1997).

Figure 3. Schematic overview (valid only for lipophilic drug or protein) of the hot and cold homogenisation technique (CitationMehnert and Mäder 2001).
Figure 3. Schematic overview (valid only for lipophilic drug or protein) of the hot and cold homogenisation technique (CitationMehnert and Mäder 2001).
Figure 4. Schematic procedure of solvent emulsification evaporation.
Figure 4. Schematic procedure of solvent emulsification evaporation.
Figure 5. Mechanism of penetration into skin.
Figure 5. Mechanism of penetration into skin.

Table II. Lipids used for preparation of nanocarrier (CitationMehnert and Mäder 2001).

Table III. List of surfactants used for preparation of lipid nanocarrier (CitationMehnert and Mäder 2001).

Figure 6. Stabilisation effect in highly concentrated lipid particle dispersions; adopted and modified from (CitationMüller et al. 2002).
Figure 6. Stabilisation effect in highly concentrated lipid particle dispersions; adopted and modified from (CitationMüller et al. 2002).

Table IV. List of drugs incorporated in NLCs (CitationGupta and Vyas 2012, CitationVarshosaz et al. 2012, CitationJia et al. 2010, CitationHan et al. 2012, CitationZhao et al. 2012, CitationChen-yu et al. 2012, CitationAraújo et al. 2011, CitationGokce et al. 2012, CitationLiu et al. 2011, CitationPardeike et al. 2011, CitationZhang et al. 2011, CitationCirri et al. 2012, CitationSouza et al. 2011, CitationNam et al. 2011, CitationSanad et al. 2010, CitationNayak et al. 2010, CitationSchäfer-Korting et al. 2007, CitationTan et al. 2010, CitationDoktorovová et al. 2010, CitationAgrawal et al. 2010, CitationTaratula et al. 2013, CitationPathak and Nagarsenker 2009, CitationZhang et al. 2010, CitationFang et al. 2008, CitationJoshi and Patravale 2008).

Figure 7. (A) TEM image of acitretin loaded NLC; adapted from (CitationAgrawal et al. 2010); (B) Cumulative percentage drug release from act suspension and Acitretin-NLC in phosphate buffer pH 7.4; adapted from (CitationAgrawal et al. 2010).
Figure 7. (A) TEM image of acitretin loaded NLC; adapted from (CitationAgrawal et al. 2010); (B) Cumulative percentage drug release from act suspension and Acitretin-NLC in phosphate buffer pH 7.4; adapted from (CitationAgrawal et al. 2010).
Figure 8. (A) The curve of the concentration of paclitaxel in plasma; (B) Distribution of PTX (Paclitaxel loaded NLCs) in tumour tissues after intravenous administration of Taxol_ or HA-NLC to mice at 0.0833, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h; adapted from (CitationYang et al. 2013).
Figure 8. (A) The curve of the concentration of paclitaxel in plasma; (B) Distribution of PTX (Paclitaxel loaded NLCs) in tumour tissues after intravenous administration of Taxol_ or HA-NLC to mice at 0.0833, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h; adapted from (CitationYang et al. 2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.